Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Recommended corrective actions could include identifying the facilities compounding the GLP-1 products, providing sample product labeling and revising or removing the misleading claims cited on its platform
It's now expecting sales and operating profit growth of 4% to 6%
Adv Funct Mater
I edited it in the original post so as not to confuse anyone else
Investor Relations, Eli Lilly and Company
A tentative FDA approval for a generic semaglutide injectable was granted to Apotex and Orbicular in 2026, but final approval cannot proceed until remaining patent protections expire or are successfully challenged in court
US$ 27.96
US$ 26.21
US$ 24.61
US$ 21.31
